Enlivex Therapeutics (ENLV) has released an update.
Enlivex Therapeutics has initiated a Phase I/II clinical trial for Allocetra™ in patients with knee osteoarthritis, successfully dosing the first two participants. This multi-center, multi-stage trial aims to evaluate the safety, tolerability, and efficacy of Allocetra™ injections in reducing joint pain and improving function. With osteoarthritis affecting millions worldwide and a lack of FDA or EMA-approved medications that can reverse joint damage, this trial represents a significant step in addressing a substantial unmet medical need.
For further insights into ENLV stock, check out TipRanks’ Stock Analysis page.
